# APPYEA, INC > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/APPYEA, INC). ## Overview APPYEA, INC is a U.S.-listed development-stage company centered on its AppySleep wristband, a biofeedback product intended to monitor and treat snoring and sleep apnea. The company’s business is built around an exclusive worldwide license held by its Israeli subsidiary to commercialize sensor and software solutions for sleep-related monitoring and treatment. Its current activity is still early-stage and highly dependent on product development, regulatory progress, and external financing rather than recurring operating scale. Recent filings show only minimal product revenue, with management focused on completing IOS design and development, building distribution, and pursuing future regulatory approvals and reimbursement pathways. ## Products & services • AppySleep biofeedback snoring treatment wristband • Sensor and software solutions for snoring monitoring • Sleep apnea monitoring and treatment solutions • Licensed sleep-analysis IP and related software • Direct-to-consumer online sales of product candidates • Distribution and commercialization arrangements - **Wearable sleep treatment device** (100%) — The AppySleep wristband is the company’s core product candidate for biofeedback-based snoring treatment. - **Sleep monitoring software and sensors** (0%) — Licensed sensor and software solutions are intended to monitor snoring and sleep apnea severity. - **Sleep apnea treatment IP** (0%) — Licensed intellectual property covers treatment solutions and speech-analysis-based severity estimation. - **Commercialization and distribution** (0%) — The company is building channels through healthcare providers, insurers, and online webstores. - AppySleep biofeedback snoring treatment wristband - Sensor and software solutions for snoring monitoring - Sleep apnea monitoring and treatment solutions - Licensed sleep-analysis IP and related software - Direct-to-consumer online sales of product candidates - Distribution and commercialization arrangements ## Customers APPYEA’s target customers are healthcare institutions, including hospitals and medical providers, that may adopt the product if it improves diagnosis and lowers care costs. The company also expects to sell directly through its website and online webstores, which points to a consumer-facing channel for individuals seeking snoring or sleep apnea solutions. In addition, management has described plans to engage private insurance plans to support reimbursement programs, suggesting payer acceptance is important to broader adoption. Because the product is still in development and commercialization is limited, customer demand is currently more prospective than recurring. - **Healthcare providers and hospitals** (primary) — They would buy or recommend the wristband and related solutions if the product improves diagnosis and reduces treatment costs. - **Direct-to-consumer buyers** (secondary) — Individuals may purchase the AppySleep wristband online for snoring and sleep apnea-related use. - **Insurance and reimbursement stakeholders** (secondary) — Private insurers and payors matter because reimbursement could materially improve adoption and affordability. - Hospitals and medical institutions seeking lower-cost sleep-related care - Healthcare providers that can validate clinical and economic value - Consumers buying directly online for snoring or sleep apnea support - Private insurers that may support reimbursement and adoption - Government health programs and commercial payors as potential reimbursement sources ## Geography The company is headquartered in the United States but its commercialization structure is international because the core license is worldwide and the subsidiary is Israeli. Management has also referenced selling through online webstores worldwide, indicating a broad addressable market rather than a single-country launch. Operationally, the company has engaged a logistical distribution facility in the U.S., which suggests the U.S. is an important near-term execution base. The intellectual property is sourced from Israeli licensors tied to Ben Gurion University and Clalit Health Services, so the business has a cross-border technology and supply chain footprint. - United States is the operating and logistics base for product distribution - Israel is the source of the licensed intellectual property and subsidiary structure - Worldwide commercialization rights support a broad addressable market - Online webstore sales are intended to reach customers globally - Cross-border IP and licensing create foreign exchange and execution exposure ## Strategy APPYEA’s near-term strategy is to finish IOS design and development of the AppySleep wristband and use financing proceeds to support general corporate needs. Management is also trying to establish distribution channels with healthcare providers and consumer specialists, while keeping a direct online sales path open. A further strategic objective is to build reimbursement support with private insurers, which would reduce adoption friction for institutional buyers and consumers. Longer term, the company is trying to convert its licensed IP into a commercial sleep-health platform, but that depends on capital availability, regulatory progress, and market acceptance. - **Complete product development** (short-term) — The company needs a finished, marketable wristband before it can scale sales or validate clinical value. - **Build commercialization channels** (short-term) — Distribution through providers and online channels is necessary to move from prototype-stage activity to sales. - **Secure reimbursement and regulatory acceptance** (medium-term) — Insurance coverage and regulatory approvals would materially improve adoption and credibility. - Complete IOS design and development of the AppySleep wristband - Build healthcare-provider distribution channels to support adoption - Sell directly through website and online webstores worldwide - Pursue reimbursement programs with private insurance plans - Advance FDA clearance and international regulatory approvals - Strengthen patent portfolio around sleep monitoring and treatment IP ## Risks The company faces substantial going-concern and financing risk because it has recurring losses, limited revenue, and current liabilities that exceed current assets. Commercial risk is also high because the business depends on whether the AppySleep wristband can achieve clinical acceptance, regulatory clearance, and reimbursement support. The licensing structure creates ongoing royalty and exit-fee obligations, which can reduce economics if the product succeeds or if the company is sold or listed on a national exchange. More broadly, the business is exposed to medical-device development risk, regulatory delays, competitive products in sleep health, and foreign exchange or cross-border execution issues tied to its Israeli IP base. - **Going concern and liquidity shortfall** [critical] — The company has recurring losses, limited cash, and management states additional capital is required to maintain operations. - **Convertible note repayment and refinancing risk** [high] — Outstanding convertible notes were extended only if the company repays principal, interest, and a premium by the new maturity date, subject to raising capital. - **Regulatory approval risk** [high] — The product is a health-related device and the company says it must pursue FDA clearance and international approvals before broader commercialization. - **Commercial adoption and reimbursement risk** [high] — Sales depend on hospitals, providers, and insurers accepting the economic and clinical case for the product. - **License economics and royalty burden** [medium] — The company owes royalties on net sales and may owe an exit fee, which can reduce future margins and transaction proceeds. - Going-concern risk due to recurring losses and limited cash resources - Need for additional capital to fund operations and repay convertible notes - Regulatory approval risk for FDA and international markets - Commercial adoption risk if providers, insurers, or consumers do not adopt the product - Royalty and exit-fee obligations under the license agreement - Foreign exchange and cross-border execution risk from Israeli operations and IP - Medical-device competition and product validation risk ## Accounting Revenue recognition is a key accounting issue because reported sales are extremely small and appear to come from delivered AppySleep wristbands, making timing of shipment and delivery important to quarterly comparability. The company also has meaningful quarter-to-quarter volatility in revenue and expenses, so small changes in product delivery or advance payments can swing reported results materially. Financial income and expenses are important because the company has convertible notes and has described derivative value changes and foreign exchange remeasurement as drivers of financial results. Investors should also watch estimates around going-concern disclosures, liability classification, and any royalty or exit-fee obligations under the license agreement, since these can affect both the balance sheet and future cash needs. - **Revenue recognition timing** — Can materially change quarter-to-quarter revenue comparability - **Convertible notes and derivative valuation** — Can create large non-operating gains or losses - **Going-concern and liability classification** — Affects investor assessment of solvency and disclosure quality - **Royalty and exit-fee obligations** — Can reduce future margins and transaction proceeds - Revenue recognition on delivered wristbands affects very small reported sales - Quarterly results can swing sharply because revenue base is minimal - Convertible notes and derivatives can create volatile financial income or expense - Foreign currency remeasurement affects monetary balances denominated in non-dollar currencies - Going-concern assessment influences liability presentation and disclosure - Royalty and exit-fee obligations under the license may create future contingent costs --- *Last updated: 2026-08-11T04:46:18.094797+00:00*